Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets Hard-to-Treat cancers with MET gene change

NCT ID NCT07196644

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will monitor side effects and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

telisotuzumab adizutecan

What this could lead to

If successful, this could provide a new treatment option for people with advanced cancers that have a specific genetic change (MET amplification).

What could go wrong

This is an early-phase trial with only 100 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING MET AMPLIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS HARBORING MET AMPLIFICATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beverly Hills Cancer Center /ID# 275465

    RECRUITING

    Beverly Hills, California, 90211, United States

  • City of Hope National Medical Center /ID# 275613

    RECRUITING

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra - Pamplona /ID# 275503

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Dell Seton Medical Center /ID# 276474

    RECRUITING

    Austin, Texas, 78701, United States

  • Duke Cancer Institute /ID# 275604

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Florida Cancer Specialists - North /ID# 277137

    RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Hadassah Medical Center-Hebrew University /ID# 274343

    RECRUITING

    Jerusalem, 91120, Israel

  • Hokkaido University Hospital /ID# 276333

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospital General Universitario Gregorio Maranon /ID# 275498

    RECRUITING

    Madrid, 28007, Spain

  • Kyoto University Hospital /ID# 276398

    RECRUITING

    Kyoto, Kyoto, 606-8507, Japan

  • Kyushu University Hospital /ID# 276302

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999

    RECRUITING

    New York, New York, 10065, United States

  • Nagoya University Hospital /ID# 276336

    RECRUITING

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital /ID# 276297

    RECRUITING

    Chuo-Ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 276298

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • Northwestern University Feinberg School of Medicine /ID# 276436

    RECRUITING

    Chicago, Illinois, 60611-2927, United States

  • Okayama University Hospital /ID# 276299

    RECRUITING

    Okayama, Okayama-ken, 700-8558, Japan

  • Rabin Medical Center. /ID# 274341

    RECRUITING

    Petah Tikva, Central District, 4941492, Israel

  • SCRI Oncology Partners /ID# 275686

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • START Midwest /ID# 276603

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Samsung Medical Center /ID# 275705

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 275703

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • South Texas Accelerated Research Therapeutics (START) /ID# 276608

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Start Mountain Region /ID# 276607

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Tel Aviv Sourasky Medical Center /ID# 274344

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 274342

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The University of Texas MD Anderson Cancer Center /ID# 275663

    RECRUITING

    Houston, Texas, 77030, United States

  • Tohoku University Hospital /ID# 276344

    RECRUITING

    Sendai, Miyagi, 980-8574, Japan

  • UT Southwestern Medical Center /ID# 276053

    RECRUITING

    Dallas, Texas, 75390, United States

  • University of Chicago Medical Center /ID# 275342

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Valkyrie Clinical Trials /ID# 275547

    RECRUITING

    Los Angeles, California, 90067, United States

  • Virginia Cancer Specialists - Fairfax /ID# 276010

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Yale University School of Medicine /ID# 275978

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Yonsei University Health System Severance Hospital /ID# 276184

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea